Mental health care company COMPASS Pathways said Monday it has received a U.S. patent for its method of treating drug-resistant depression using a psilocybin formulation.
The patent includes the use of Compass' synthesized investigational psilocybin formulation COMP360 that targets patients with treatment-resistant depression.
The company previously reported that COMP360 provoked no serious adverse events.
Don’t miss out on the top cannabis stories of the day. Click here to sign up for our daily insider newsletter.
COMPASS is still conducting a Phase IIb clinical trial of COMP360 in treatment-resistant depression with 216 patients.
"Too many people are suffering with treatment resistant depression. We are committed to developing innovations, such as psilocybin therapy, to address this rapidly growing problem,” George Goldsmith, CEO and co-founder of Compass, said in a statement.
“Patents help ensure sustainable funding to conduct the highest quality clinical research to bring the best new therapies to patients who urgently need them. If this research demonstrates psilocybin therapy is a safe and effective option for patients, we will price it responsibly with the goal of making it as affordable and accessible as possible."
Photo via Wikimedia.
See more from Benzinga
- Organigram Analysts Say Stock's Post-Earnings Rally 'Overdone,' Company Should Add Leverage
- Carlos Santana, Left Coast Partner On Cannabis, Hemp CBD Products Inspired By Musician's Latin Heritage
- Tilray Expands Leadership Team With Former Executives At Molson Coors, Revlon
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.